SWA
CRSP icon

SOA Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

SOA Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.45K Hold
155
– – ﹤0.01% 635
2026
Q1 		$7.37K Buy
+155
New +$8.18K ﹤0.01% 624
2022
Q4 		– Sell
-18
Closed -$1K – 986
2022
Q3 		$1K Hold
18
– – ﹤0.01% 755
2022
Q2 		$1K Buy
+18
New +$1.06K ﹤0.01% 743

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SOA Wealth Advisors's CRSP Position: Q2 2026 in Review

SOA Wealth Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 155 shares worth $8.45K. The position accounts for ﹤0.01% of the portfolio, ranked #635.

SOA Wealth Advisors first reported a position in CRSP in Q2 2022 and has held it in 4 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SOA Wealth Advisors held 155 shares of CRISPR Therapeutics worth $8.45K as of Q2 2026.
  • SOA Wealth Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of SOA Wealth Advisors's portfolio in Q2 2026, its #635 holding.
  • SOA Wealth Advisors first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 4 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SOA Wealth Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.